- |||||||||| ASP9801 / Astellas, Tottori University
Trial completion date, Trial primary completion date, Combination therapy, Oncolytic virus, Metastases: KEYNOTE-B26: A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors (clinicaltrials.gov) - Feb 15, 2024
P1, N=72, Active, not recruiting,
Active, not recruiting --> Completed Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Aug 2024 --> Apr 2024
- |||||||||| ASP9801 / Astellas, Tottori University
Enrollment change, Combination therapy, Oncolytic virus, IO biomarker, Metastases: KEYNOTE-B26: A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors (clinicaltrials.gov) - Apr 5, 2023
P1, N=72, Active, not recruiting,
Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Aug 2024 --> Apr 2024 N=260 --> 72
- |||||||||| ASP9801 / Astellas, Tottori University
Enrollment closed, Combination therapy, Oncolytic virus, IO biomarker, Metastases: KEYNOTE-B26: A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors (clinicaltrials.gov) - Mar 9, 2023
P1, N=260, Active, not recruiting,
N=260 --> 72 Recruiting --> Active, not recruiting
- |||||||||| ASP9801 / Astellas, Tottori University
Enrollment change, Combination therapy, Oncolytic virus, IO biomarker, Metastases: KEYNOTE-B26: A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors (clinicaltrials.gov) - Mar 22, 2022
P1, N=260, Recruiting,
Recruiting --> Active, not recruiting N=105 --> 260
- |||||||||| ASP9801 / Astellas, Tottori University
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Oncolytic virus, IO biomarker, Metastases: KEYNOTE-B26: A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors (clinicaltrials.gov) - Sep 2, 2020
P1, N=105, Recruiting,
N=105 --> 260 Active, not recruiting --> Recruiting | Trial completion date: Mar 2023 --> Oct 2024 | Trial primary completion date: Mar 2022 --> Oct 2024
- |||||||||| ASP9801 / Astellas, Tottori University
Enrollment closed, Combination therapy, Oncolytic virus, IO biomarker, Metastases: KEYNOTE-B26: A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors (clinicaltrials.gov) - May 6, 2020
P1, N=105, Active, not recruiting,
Active, not recruiting --> Recruiting | Trial completion date: Mar 2023 --> Oct 2024 | Trial primary completion date: Mar 2022 --> Oct 2024 Recruiting --> Active, not recruiting
- |||||||||| ASP9801 / Astellas, Tottori University
Enrollment open, Combination therapy, Oncolytic virus, IO biomarker, Metastases: KEYNOTE-B26: A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors (clinicaltrials.gov) - Jun 26, 2019
P1, N=105, Recruiting,
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
|
